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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis 
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Streptococcus agalactiae or GBS 
Rebecca Lancefield	
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Group B streptococcal diseases in 
neonates 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
§  Maternal morbidity  
§  Along pregnancy  
§  Peripartum 
§  Serious diseases among elderly and adults with 
underlying diseases 
§  Significant mortality 
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GBS Neonatal Infections  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
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80 % EOD	

EOD : 80-90 % occur  




GBS Neonatal Infections 	  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
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Burden of neonatal  GBS early onset 
diseases in European countries 




Spain 2 (1996) to 0.45 
(2008)  
Lopez Sastre et al. 
Acta Pediatr 2005 
Belgium 2 Melin, Indian J Med 
Res 2004 
Eastern Europe 0.2 - 4 Trijbels-Smeulders, 
Pediatr Infect Dis J 
2004 Western Europe 0.3 - 2 
The Netherlands  1.9 
Scandinavia 0.76 - 2 
Southern Europe 0.57 - 2 
Data assessing more accurately the true burden are needed 
 
-  Carriage rate ? 
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40 - 60 %!60 - 40 %!
GBS EOD vertical transmission 
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AsymptomaGc	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  verGcal	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40 - 60 %!
2 - 4 %!
GBS EOD 
60 - 40 %!
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GBS maternal colonization 
Risk factor for early-onset disease (EOD) : 
vaginal GBS colonization at delivery 
 
§  GBS carriers  
§  10 - 35 % of women 
§  Clinical signs not predictive 
§  Dynamic condition 
§  Intestinal reservoir 
§  Prenatal cultures late in pregnancy can predict 
delivery status 
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Additional Risk Factors  
for Early-Onset GBS Disease 
  Obstetric factors:  
  Prolonged rupture of  
membranes,  
  Preterm delivery,  
  Intrapartum fever 
  GBS bacteriuria 
  Previous infant with GBS disease 
  Immunologic:  
  Low specific IgG to GBS capsular 
polysaccharide 
No difference in occurrence either in GBS 
Positive or Negative women, except 
intrapartum fever 
Lorquet S., Melin P. & al. 	
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GBS EOD - Belgian data 
§  Incidence 
§  1985 -1990: 3/1000 live births 
§  1999, estimation : 2/1000 live births 
§  2010, estimation : < 1/1000 live births  
§  Meningitis : 10 % 
§  Mortality : 5 -10 % 
§  60 % EOD (130 cases) : WITHOUT any maternal/
obstetric risk factor except colonization 
§  Prenatal screening 
§  Recto-vaginal cultures : 13-35 % GBS Positive 
P. Melin -  2001, 2007 - Reference laboratory for GBS.	
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GUIDELINES FOR PREVENTION 
OF GBS PERINATAL DISEASE 
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pathogenesis 
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-  C5a peptidase 
-  ….. Bacteria 
Peptidoglycan 
β-hemolysin, … 
IL1, IL6, TNF α, 
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Which prevention 
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GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 
different virulence factors (pili, scpB, …) 
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 Intrapartum  antibioprophylaxis 
> 4 (2) hours before delivery 
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GBS  
pathogenesis 
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Prevention of perinatal GBS EOD	  
§  Intrapartum antibiotics 
§  Highly effective at 
preventing EOD in 
women at risk of 
transmitting GBS to 
their newborns ( > 4 h) 
(clinical trials in late 80s) 
Who is  
the women  
at risk ? 
Risk-based strategy  
or 
Screening-based strategy 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   Consensus   
   guidelines: 
- Screening  
-Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  
more effective  
than RF 
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Why is Screening more protective 
than the risk-based approach ? 
Schrag	  S.	  et	  al.	  N	  Engl	  J	  Med	  2002;	  347:233-­‐9	  
Broader coverage of « at-risk » population 
Ø  Captures colonized women without obstetric RF 
Ø  High level of compliance with recommendations 
Ø  Enhanced compliance with risk-based approach 
cannot prevent as many cases as universal 
screening 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 
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CDC, USA, MMWR, Vol 59 
(RR-10) August 2010 
Endorsed by 
  - AAP  
  - ACOG 
 
            SHC, Belgium July 2003 
Revision ongoing 
department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
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European strategies 
for prevention of GBS EOD 
§  Intrapartum antibioprophylaxis recommended 
§  Screening-based strategy 
§  Spain, 1998, 2003, revised 2012 
§  France, 2001 
§  Belgium, 2003, revision ongoing 2012 
§  Germany, 1996, revised 2008 
§  Switzerland, 2007  
§  Risk-based strategy 
§  UK, the Netherlands, Denmark 
§  No guidelines 
§  Bulgaria, … 
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Universal screening-based strategy for 
prevention of GBS perinatal disease 
Vagino-rectal GBS screening culture  at 35-37 weeks of gestation  
 
For ALL pregnant women 
> 1 Risk factor:  
   - Intrapartum fever > 38°C*** 
   -  ROM > 18 hrs 




























if NO! if YES!
Unless patient had a previous infant with GBS invasive disease  
 or GBS bacteriuria during current pregnacy 
 or delivery occurs < 37 weeks’ gestation * 
GBS Neg 
if  YES!
GBS POS Not done, incomplete or 
unknown GBS result 
! Facultative !  
Intrapartum rapid GBS  test** 
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Remaining burden of GBS EOD 
Missed opportunities 
In spite of universal screening prevention 
strategy 
In spite the great progress 
 Cases still occur 
§  Among remaining cases of EOD 
§  Some may be preventable cases 
§  Missed opportunities for (appropriate) IAP 
§  False negative screening 
Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 
CDC revised guidelines 2010 
Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 
DEVANI project, unpublished data 2011 
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SCREENING  
FOR GBS COLONIZATION 









29	  	  	  	  	  	  	  	  INTRODUCTION	  &	  BURDEN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GUIDELINES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SCREENING	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VACCINE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CONCLUSION	  CEPHEID 2.10.2012 
Antenatal GBS culture-based 
screening 
Goal of GBS screening 
To predict GBS vaginal (rectal) colonization at the 
time of delivery 
§ 	  Critical factors influencing accuracy 
§  Swabbed anatomic sites 
§  Timing of sampling 




§  Non-culture  
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From direct plating on blood agar 
Evolution of culture methods 	  
Use of selective enrichment broth 
§  To maximize the isolation of GBS 
§  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
Pigment-­‐based 	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chromogenic	  media	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Which agar or which combination? 
+/- Blood agar 
 
Workload - costs - extra-testing - non β-hemolytic  
GBS detection  to be considered 
	  	  	  	  	  	  	   SCRE I  
32	  	  	  	  	  	  	  	  INTRODUCTION	  &	  BURDEN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GUIDELINES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SCREENING	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  VACCINE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CONCLUSION	  CEPHEID 2.10.2012 
§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart or Granada 
 like tube) (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
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Prenatal culture-based 
screening: Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
§  Failure of GBS culture  (oral ATB, feminine hygiene) 
or new acquisition 
§  Up to 1/3 of GBS positive women at time of delivery 
§  Continuing occurrence of EO GBS cases 
§  False-positive 
§  Unnecessary IAP 
Need for more accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  colonizaGon	  
	  	  	  	  	  	  	   SCRE I  
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  CEPHEID 2.10.2012 
Prenatal culture-based 
screening: Limiting factors 
§  Unknown GBS status at presentation for 
delivery 
§  Screening performed but result not available 
§  Women with no prenatal care 
Risk based strategy  
•  60% at GBS risk not identified 
•  > 10% of unnecessary IAP 
Need for rapid accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  colonizaGon	  
	  	  	  	  	  	  	   SCRE I  
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Alternative to GBS prenatal 
screening: intrapartum screening 
Theranostic approach 
Turnaround time 








30-45 minutes, 24 hrs/7 d, robust 
Benitz et al. 1999, Pediatrics, Vol 183 (6) 
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§  Identification of women without prenatal screening/
care 
§  Inclusion of women with change of GBS status after 
35-37 wks gestation 
§  Increased accuracy of vaginal GBS colonization 
status at time of labor & delivery 
 
Intrapartum screening theranostic 
approach: expected advantages 
IAP addressed to right target 
§  Reduction of inappropriate/unnecessary IAP 
§  Broader coverage of « at GBS risk women »  
Improvement of prevention  
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Real Time PCR for intrapartum 
screening 
§  Advance in PCR techniques & development of 
platforms 
§  BD GeneOhmTM Strep B Assay (+/- 1 hr) (in laboratory) 
§  Xpert GBS, Cepheid (35-45 min) (can be performed as a POCT)  
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Xpert GBS for intrapartum screening 
Diagnostic Accuracy of a Rapid Real-Time Polymerase Chain 
Reaction Assay for Universal Intrapartum Group B Streptococcus 
Screening  
Najoua El Helali, Jean-Claude Nguyen, Aïcha Ly, Yves Giovangrandi and 
Ludovic Trinquart   
Clinical Infectious Diseases 2009;49:417–23 
 
	  	  	  	  	  	  	   SCRE I  
§  968 Pregnant women  
§  Intrapartum Xpert GBS, Cepheid  (performed in lab) 
§  vs intrapartum culture        prenatal culture (French recom.) 
              (vaginal swab/CNA-BA) 
§  Sensitivity   98.5% 
§  Specificity   99.6% 
§  PPV     97.8%    PPV    58.3% 
§  NPV     99.7%    NPV    92.1% 
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Cost and effectiveness of intrapartum group B streptococcus 
polymerase chain reaction screening for term deliveries. 
El Helali N, Giovangrandi Y, Guyot K, Chevet K, Gutmann L, Durand-
Zaleski I 
Obstet Gynecol 2012 Apr;119 (4):822-9 
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Xpert GBS for intrapartum screening 
           2009               2010  
Antenatal screening    Xpert GBS intrapartum screening 
        Performed by midwives as a POCT !! 
11.7% GBS POS     16.7% GBS POS 
        Less GBS EOD & less severe 
 
                        Cost neutral per delivery 
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Real-Time PCR Assay Provides Reliable Assessment of Intrapartum 
Carriage of Group B Streptococcus  
Michelle J. Alfa, Shadi Sepehri, Pat De Gagne, Michael Helawa, Gunwat 
Sandhu, and Godfrey K. M. Harding  
JCM, Sept. 2010, p. 3095–3099 
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Xpert GBS for intrapartum screening 
§  205 Pregnant women  
§  Intrapartum Xpert GBS, Cepheid 
§  vs intrapartum culture     
 24.5% GBS pos   (vagino-rectal swab/LIM) 
§  Sensitivity   91.7% 
§  Specificity   99.3% 
§  PPV     97.7%      
§  NPV     97.3%     
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Real-­‐Gme	  PCR,	  very	  promising,	  but	  …	  
§  Rapid, robust & accurate technology 
§  Still an expensive technology (specific equipment) 
§  Cost effective ?  
§  Need for more cost-effective clinical study 
§  Logistic 
§  24 hours 7 days 
§  In the lab? 
§  In the obstetrical department as a POCT ? 
§  In combination with prenatal screening strategy ? 
§  CDC 2010 
§  No antimicrobial result  
§  In the future detection of R genes, but mixed microbiota ! 
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CONCLUSION 
Take home messages 
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In Europe, as globally	  
§  Neonatal GBS diseases  
§  EOD and LOD, a public health concern 
§  IAP efficient for prevention of EOD 
§  Best strategy still a matter of debate  
§  Not 100% efficient 
§  No effect on LOD 
§  IAP not widely recommended 
§  Need better data assessing more 
accurately the true burden 
§  GBS vaccine eagerly expected   
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Summary	  
“Screening” Prevention strategies 
 
§  Culture-based GBS prenatal screening 
§  To optimize critical factors 
§  Improved by selective differential agars 
§  False +/False - ! 
 
§  Rapid intrapartum screening 
“From a dream to reality” 
§  Real time PCR 
§  Yes but costs, logistic, … 
§  Need for more clinical trial and cost 
effectiveness evaluation 
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Prevention of perinatal GBS EOD	  




Main goal :  
§  To prevent 70 to 80 % of GBS EO cases 
Secondary : 
§  To reduce peripartum maternal morbidity 
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Intrapartum IV Antibio-Prophylaxis 
(CDC 2010, Belgian SHC 2003)	  
§  Penicillin G 
§  5 millions U, IV initial dose, then 2,5 to 3 millions U IV every 4 
hours until delivery. 
§  Ampicilline   
§  2 g IV initial dose, then 1 g IV everye 4 h until delivery. 
§  Acceptable alternative , but broader spectrum, potential selection of R 
bacteria 
§  If penicillin allergy 
§  Patients at low risk for anaphylaxis 
§  Cefazolin, 2 g IV initial dose, then 1g IV every 8 h until delivery.  
§  Patients at high risk for anaphylaxis  
§  Clindamycin, 900 mg IV every 8 hours until delivery. 
§  If GBS resistant to clindamycin : use vancomycin 
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